Lingyu Ding

Hangzhou, 310002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Cancer-associated fibroblasts as a critical driver in tumor metastasis: The mechanisms and future perspectives.

Cancer-associated fibroblasts as a critical driver in tumor metastasis: The mechanisms and future perspectives.

Journal: iScience

Published: February 18, 2026

Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer.

Associations between plasma markers and symptoms of anxiety and depression in patients with breast cancer.

Journal: BMC psychiatry

Published: May 28, 2024

Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinoma.

Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinoma.

Journal: Cancer letters

Published: May 26, 2022

Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.

Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.

Journal: JAMA network open

Published: October 07, 2020

Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.

Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.

Journal: British journal of cancer

Published: December 18, 2019

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.

Journal: Oncotarget

Published: October 20, 2016

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.

Journal: Oncotarget

Published: April 21, 2015

The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).

The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Published: October 09, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026